March 25, 2021 shields

Dermatology Landscape: Continued Growth Within the Excelera Network

This blog was written by Excelera, a Shields company.

Last month, the American Academy of Dermatology (AAD) was poised to have its 79th annual meeting. Unfortunately, the meeting was canceled due to continued COVID-19 restrictions, but it afforded our team an opportunity to delve into an analysis of the Excelera Network and a growing disease state, dermatology. Not surprising, our data trend followed a 2019 survey of health system specialty pharmacies in which one in three surveyed providers forecasted growth in dermatology at an average rate of 27%¹. In 2020, the Excelera Network covered over 33,000 fills across nearly 6,000 dermatology patients which represented a gross revenue north of $200,000,000 for the year, making it a relatively robust therapeutic class in the Excelera Network.

Excelera Network Analysis: Dermatological Landscape
March also marked the one year anniversary of the beginning of the COVID-19 pandemic. While disease states such as oncology were acutely affected by the pandemic and the resulting stay-at-home orders (see our past blog post about this here), counts of dermatology fills, patients, and providers were consistently up, even while controlling for the growth of our network membership. Additionally, dermatology revenue in 2020 was the highest yet for this therapy class within the Excelera Network, up 38% from the same total in 2019. This year, the Excelera Network is on pace to exceed the 2020 total, based on a machine learning-based forecast of the monthly adjudication amounts.

The Excelera Network also saw considerable diversity in terms of prescribing providers with multiple different specialties within dermatology. These providers² represent roughly 1 in 10 of the patients studied in 2020. Note, the values in the infographic represent only data from dermatological providers within the Excelera Network.

We will continue to monitor the growth of dermatology and health system specialty pharmacy, but the future looks bright for this particular disease state.

For more information about the Excelera Network, contact us at info@excelerarx.com.

Sources: ¹ CSI State of Specialty Pharmacy 2019, ² Provider specialty determined using NPPES Provider Registry